Table 1.
Baseline characteristics
|
Part 1: single ascending doses |
Part 2: IBSM |
||||||
|---|---|---|---|---|---|---|---|
| DSM265 (n=55) | Placebo (n=18) | Total (n=73) | DSM265 (n=7) | Mefloquine (n=2) | Total (n=9) | ||
| Age (years) | 26·1 (6·8) | 27·9 (8·9) | 26·6 (7·3) | 24·1 (2·0) | 27·0 (5·7) | 24·8 (2·9) | |
| Race | |||||||
| White | 47 (85%) | 15 (83%) | 62 (83%) | 7 (100%) | 1 (50%) | 8 (89%) | |
| Asian | 6 (11%) | 1 (6%) | 7 (10%) | 0 | 1 (50%) | 1 (11%) | |
| Black African | 2 (4%) | 0 | 2 (3%) | 0 | 0 | 0 | |
| Pacific Islander | 0 | 2 (11%) | 2 (3%) | 0 | 0 | 0 | |
| Height (cm) | 177·9 (6·4) | 179·6 (6·1) | 178·3 (6·4) | 175·0 (8·3) | 181·0 (7·1) | 176·3 (8·1) | |
| Bodyweight (kg) | 78·7 (11·1) | 79·1 (11·2) | 78·8 (11·0) | 73·5 (10·8) | 77·3 (8·3) | 74·4 (10·0) | |
| Body-mass index (kg/m2) | 24·8 (3·0) | 24·5 (3·0) | 24·8 (3·0) | 23·9 (2·4) | 23·6 (0·6) | 23·8 (2·1) | |
Data are n (%) or mean (SD). All participants were male. IBSM=induced blood-stage malaria.